Not Just the Mind: How Antipsychotics Affect Oral Health

Research

A study by the University of the Basque Country (Bilbao, Spain) aims to systematize the oral side effects associated with the use of antipsychotic drugs and to fill the knowledge gap regarding the direct impact of these medications on the oral mucosa, salivary gland parenchyma, and periodontium.

Key findings

• Salivation disorders: hyposalivation/xerostomia are more frequently reported, while changes in saliva quality and composition are less common. This increases the risk of caries, candidiasis, and complications with dental prosthetics.
• Inflammatory changes: signs of mucositis and enhanced gingival and periodontal inflammatory response were identified, potentially exacerbated by poor oral hygiene in patients with mental disorders.
• Increased frequency of tooth loss: associated with the combined effects of xerostomia, progression of periodontitis, and inadequate dental care.
• Association of specific drugs with characteristic oral manifestations: The authors note that different antipsychotics have varying effects on the oral mucosa, salivation, and motor control of the oral musculature (extrapyramidal disorders). However, the brief summary does not provide a complete list of medications or quantitative data.

Study limitations

The brief summary lacks detailed methodology, a specific list of medications, dosages, and statistical data; this limits the ability to directly extrapolate the findings to individual clinical decisions.

Implications for dental practice

For the dental clinician, it is important to consider medication history when assessing risk factors for oral diseases in patients receiving antipsychotic therapy.

Recommendations for assessment and monitoring

• Systematically document the use of antipsychotics and concomitant pharmacotherapy, paying attention to the anticholinergic burden.
• Assess salivary gland function: history of xerostomia, objective assessment of saliva volume, and referral for sialometry tests if necessary.
• Perform a thorough periodontal assessment and periodically schedule more frequent check-ups and professional hygiene sessions for patients at increased risk.
• Monitor for signs of candidiasis, mucosal lesions, and mucosal trauma, including those associated with hyperkinesias (tardive dyskinesia) and bruxism.

Expert commentary

Potential mechanisms

The likely mechanisms include muscarinic receptor antagonism and other anticholinergic effects leading to reduced saliva production; neurotransmitter changes affecting motor control of the oral musculature (extrapyramidal symptoms); as well as mediated deterioration of hygiene and nutrition in patients with severe psychiatric symptoms.

Practical measures

• Include xerostomia management strategies in the treatment plan: prescribing replacement therapy (saliva substitutes), encouraging sugar-free gum if no contraindications exist, and recommending frequent fluid intake.
• Implement caries and periodontitis prevention: topical fluoride applications, remineralizing therapy, and personalized oral hygiene instructions.
• Treat or prevent candidiasis upon clinical signs: antifungal therapy according to clinical guidelines.
• Upon detection of pronounced extrapyramidal symptoms or suspicion of drug-induced motor impairments, initiate communication with the treating psychiatrist to assess the feasibility of therapy adjustment.
• Consider the impact of medications when planning prosthetics: assess the risk of salivary dysfunction and the possibility of candidiasis; select materials and designs taking into account the increased risk of complications.

Clinical integration

Incorporating questions about psychotropic therapy into the standard dental history, fostering interdisciplinary collaboration with psychiatrists and pharmacologists, and adapting preventive programs will help reduce dental complications and improve the quality of life for patients on antipsychotic therapy.